An Open-Label, Phase 1/2 Study of ORIC-114 as a Single Agent or in Combination With Chemotherapy, in Patients With Advanced Solid Tumors Harboring an EGFR or HER2 Alteration

15354ORIC-114-01-NCT05315700OpenAn Open-Label, Phase 1/2 Study of ORIC-114 as a Single Agent or in Combination With Chemotherapy, in Patients With Advanced Solid Tumors Harboring an EGFR or HER2 AlterationORIC-114-01NCT05315700IndustrialAdultTreatmentI/IIMultipleKim, ChulGeorgetown University Medical Center : Jeanette Crawford; Lombardi Comprehensive Cancer Center : Jeanette CrawfordThoracic/CNS/H&N/ThyroidOncology GroupLombardi Comprehensive Cancer Center (LCCC); Oncology PFS6888Jeanette CrawfordJeanette Crawford+1 202-687-0893crawfojg@georgetown.eduResearch Nursing Coordinator 2026.1.0 Build 16 <a href="https://advarra.com" target="_blank">© 2026 Advarra, Inc.</a>